Investigational New Drugs

Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia

• Research

Seyda Gungordu, Erhan Aptullahoglu

Clinical research progress of fruquintinib in the treatment of malignant tumors

• Open Access
• Research

Shihao Zhao, Wenhui Wang, Jingyi Li, Zhigang Li, Zhanbo Liu, Shunchao Zhang, Zhaoqi Chen, Hongling Wang, Xiangqi Wang, Juntao Wang

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma

• Research

Cong Fu, Haoran Gu, Lin Sun, Zhouyu Wang, Qin Zhang, Ningning Luo, Dongsheng Chen, Tong Zhou

Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients

• Open Access
• Research

Mohamed Ali Badawi, Benjamin Engelhardt, Edyta Dobkowska, Rong Deng, Jonathan L. Kaufman, Rajeev Menon, Ahmed Hamed Salem

Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models

• Open Access
• Research

Salma Begum, Scheldon D. Irvin, Carol K. Cox, Zhouyang Huang, Justin J. Wilson, Jerry D. Monroe, Yann Gibert

A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy

• Research

Satoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, Takahiro Tsushima, Kunihiro Fushiki, Tateaki Naito, Akira Ono, Nobuhiro Kado, Yusuke Onozawa, Haruyasu Murakami, Toshiaki Takahashi, Yasuyuki Hirashima, Keita Mori, Kentaro Yamazaki

Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial

• Research

Mathilde Morisseau, Carlos Gomez-Roca, Marie Viala, Audrey Rabeau, Delphine Loirat, Nadia Munsch, Kristell Thomas, Cécile Pages, Iphigenie Korakis, Vincent Sibaud, Jean-Pierre Delord, Thomas Filleron, Bastien Cabarrou

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer

• Research

Elisabeth I. Heath, Wei Chen, Jae E. Choi, Kimberlee Dobson, Melanie Smith, Tomasz Maj, Ilona Kryczek, Weiping Zou, Arul M. Chinnaiyan, Yuanyuan Qiao

Manganese improves anti-PD-L1 immunotherapy via eliciting type I interferon signaling in melanoma

Xiaoxin Zhang, Jianhua Deng, Renjie Wu, Jian Hu

Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate

• Research

Shaoshi Chen, Qi Zhong, Shurong Zhang, Yang Zhang, Lizhen Hou, Hongzhi Ma, Shizhi He, Meng Lian, Yurong He, Ru Wang, Jugao Fang

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study

Manyi xu, Yanhua Wang, Ke Wang, Yue Hao, Chunwei Xu, Lei Shi, Zhengbo Song

Gremlin1: a BMP antagonist with therapeutic potential in Oncology

• Review

Zhao Jin, Yanshuo Cao

Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review

• Review

Jian-rong Na, Yaqin Liu, Kun Fang, Yuan Tan, Pan-pan Liang, Mei Yan, Jiao-jiao Chu, Jian-mei Gao, Dongsheng Chen, Shu-xiang Zhang